3 Stocks With Huge Analyst Upside Potential

 WallStWhiz
 
  WallStWhiz
 
Follow  Message
 
 
 
Unraveling market complexities one story at a time. Reporting on finance with integrity and insight.
 

•  27 May 2025
 

Analyst targets are flashing big upside for a few under-the-radar names. With earnings around the corner and sentiment shifting, let’s break down which stocks are drawing Wall Street’s confidence and where the smart money might be headed next.

$ANF Abercrombie & Fitch 83.65% Upside Potential
Abercrombie & Fitch is back in the spotlight with earnings due Wednesday, and Wall Street's expectations are... sky-high. Despite a jaw-dropping 59.87% pullback from its 52-week highs, analysts are holding strong with 13 Buy ratings and a $134.38 price target, suggesting 83.65% upside from current levels.

The brand has beaten earnings in recent quarters, but strangely, the stock dropped after those beats — a sign that guidance has become the key catalyst. This week’s report will be crucial. Investors are looking for solid top-line growth and a bullish outlook into the back half of the year.

If ANF nails guidance and macro headwinds ease, the recovery potential could be explosive.

$CCLD CareCloud 139% Upside Potential
Small-cap AI healthcare player CareCloud may not be on every trader’s radar — but it should be. At just $2.09, analysts remain bullish with a DCF-based price target of $5.00, implying a 139% upside. Recent interviews with leadership confirmed their focus on embedding AI across workflows, targeting more efficient operations and stronger margins.

With its unique position in processing millions of healthcare claims monthly and a clear product roadmap, CCLD stands out in a sector where peers are trading at much higher multiples. Momentum is also on its side, with the stock trending upward and RSI comfortably sitting at 57.

As AI and healthtech converge, this could be a deep-value play with breakout potential.

$CRM Salesforce 24.25% Upside Potential
Salesforce is prepping to report earnings this Wednesday, and the Street is cautiously optimistic. After a mild 0.13% gain in the past year, the stock remains in a consolidation zone. But the analyst crowd still sees 24.25% upside with a $339.36 average target.

Despite beating EPS last quarter, CRM saw a surprising sell-off, showing investors are less interested in past performance and laser-focused on forward guidance. With AI CRM and efficiency pushes in play, any improvement in margins or outlook could reignite investor interest.

CRM isn’t flashy right now, but it’s coiled and a strong report could unlock a big move.